Insulin Syringes Market by End Users (Hospital, Homecare, and Others); By Distribution Channel(Online, Offline); By Region (U.S., Canada, Mexico, UK, France, Germany, Italy, Spain, Benelux Union, Nordic Countries , Rest of Europe, China, Japan, India, South Korea, Singapore, Philippines, Indonesia, Thailand, Malaysia, Vietnam, Rest of Southeast Asia, Brazil, Argentina Rest of Latin America, GCC countries, Southern Africa, Rest of Middle East & Africa) – Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2019 - 2027
Industry Insights
Global Insulin Syringes Market was valued at US$ 25143.41 million in 2018 and is expected to reach US$ 89132.64 million by 2027, growing at an estimated CAGR of 14.9% over the forecast period.
Insulin Syringes Market is expected to see a robust growth due to several factors, such as increased demand for pre-filled syringes and rising prevalence of chronic diseases. In addition, it is also seen that adoption of injectable drugs, increased geriatric population and technological advances of syringes is positively impacting the market. An insulin syringe helps to administer insulin in doses needed to diabetic patients. Insulin syringes are made of three parts - a needle, a tube, and a plunger and are available in different sizes. The size of insulin syringe to be given to diabetic patients is selected based on the required insulin dose. Major factors fueling the market growth are ageing population and the increasing number of patients with diabetes globally. Increasing incidence of obesity and people following an unhealthy lifestyle additionally supports Insulin Syringes Market growth. In the initial stages of diagnosis of diabetics when the blood glucose levels of patient are not very high, it is advisable to control the blood sugar levels with the help of regular physical activities and appropriate dietary modifications. However, when diet and physical activities are not able to control patient’s blood sugar, it is advised to take oral anti diabetic tablets or insulin syringes that can help patients to reach their blood glucose targets. The syringe used for insulin injection are disposable in nature to avoid any kind of infection.
Prefilled syringes are the latest products which have been introduced by medical device firms. These syringes contain the exact amount of drug dosage which would greatly benefit the patients. Vaccinations along with biologics are available in pre-filled syringes. Prefilled syringes ensure minimal drug wastage. Another major advantage of Prefilled syringe is the minimal risk of contamination. Due to these factors, medical professionals are slowly shifting towards prefilled syringes. These are generally preferred for parenteral administration of various drugs and are primarily used for the treatment of diabetes where patients have to administer medication themselves, several days a week. Pharmaceutical companies are focused on getting developments in self-administration therapies in line with this trend. The latest trend that is gaining momentum on the Insulin Syringes Market is the change from prefilled glass syringes to pre-filled plastic syringes. Due to the introduction of advanced polymer materials including polypropylene and crystal-clear polymer, which are biocompatible with the other components of the syringe, the plastic prefilled syringes are becoming more common. In recent years syringes made of polymer have gained popularity in the medical practice, theses syringes free from majority of shortcomings inherent to glass syringes. As compared to glass syringes which have high cost, medical practitioners are preferring polymer syringes. Reusable plastic syringes are not preferred for insulin injection because of sterilization complexities after single use.
Increasing diabetic population
The major factors fuelling Insulin Syringes Market growth are the increasing aging population and the increasing number of patients with diabetes globally. Increase in the incidence of obesity and people following an unhealthy lifestyle additionally supports market growth. According to WHO In 2014, 8.5% of adults aged 18 years or more had diabetes. In 2016, diabetes directly cause the death of 1.6 million people and in 2012 high blood glucose was the cause of another 2.2 million deaths. In 2019 a day before world diabetic day on 13th November, WHO announced to start of a programme to prequalify human insulin for the treatment of population in low and middle-income countries. According to American Diabetic Association Although type 2 diabetes used to be prevalent among older adults, but currently it has become quite common among adolescents and younger adults due to rising levels of obesity and unhealthy diet.
Technological advancements
Initially insulin syringes were not accepted by majority of population due to fear factor. However with the technological advancement, current insulin needles are very fine and the injection prick is very less painful which has boosted the Insulin syringe market significantly. The increase growth in insulin syringe is also due to the recent guidelines issued by major international health organizations such as American Diabetes Association (ADA) which advocates to opt for insulin at the early stage of diabetes, this can help in preventing diabetes complications which may affect the vital organs of body.
High Costs of insulin
The cost of insulin has always been a major concern for the patients. As the price of insulin continues to rise, individuals with diabetes are often forced to choose between purchasing their medications or paying for other necessities, exposing them to serious short- and long-term health consequences. High costs of advanced insulin syringes limit the insulin syringe market expansion. Currently only three pharmaceutical companies – Novo Nordisk A/S, Eli Lilly and Company. and Sanofi have control over most of the global market for insulin products, and prevailing prices remain prohibitive for many people of low-income countries, which is also there in some high-income groups as well. The steps required to take insulin through a syringe are much more complicated than insulin pens which allows more simple, accurate, and convenient delivery than using a vial and syringe this causes restraint in the growth of Insulin syringe market.
By end user
One of the critical part of diabetes treatment is Insulin therapy which is necessary in case of type 1 diabetes patients and also for many type 2 diabetes patients the goal of the therapy is to keep sugar level in control. Hospital segment represents the largest segment due to the increase in number of people having type 1 diabetes which require specialized insulin treatment which is only possible under the guidance of specialized practitioners/doctors. It is advised while looking for the hospitals for diabetes treatment always consider to consult with specialized glucose or diabetes control management team. Hospitals accounted for major share in the global insulin Syringes Market in 2018 and is expected to show sustainable growth during the forecast period expanding at a CAGR of xxx from 2019 – 2027
Offline Distribution Channels
Offline distribution channel has been a major contributor in the growth of insulin syringe market. This is due to the trust of patients on offline pharmacy stores as compared to online pharmacies while buying any type of medications. The offline distribution segment is expected to grow at a rate of xxxx during the forecasted period
Regional Insights
During the forecast period, the Asia-Pacific syringes market is expected to show strong growth. In last three decades there has been huge rise in the diabetic population, according to American diabetic association; there is expected rise of 150% rise in type 2 diabetic population between 2000 and 2035 in South Asia. The international diabetes federation says that there were more than 380 million people with diabetes in 2013. More than 60% of the total diabetic population lives only in Asia with almost half of them are residing in India and China. While the syringe market is currently in its infancy stage at APAC, factors such as improving economic conditions, growing people's purchasing power, increasing awareness of the benefits of prefilled syringes, and the presence of a large pool of patients suffering from various chronic diseases are expected to drive the Insulin Syringes Market to register a double-digit CAGR. In Asia-Pacific, Japan accounts for both revenue and volume as a major market share, owing to increased demand for self-administered treatments and high penetration of self-injection products, rising aging population, and increasing diabetes prevalence.
Insulin Syringes Market Revenue & Forecast, (US$ Million), 2015 – 2027
Competitive Landscape
The report provides both, qualitative and quantitative research of insulin syringes market, as well as provides comprehensive insights and development methods adopted by the key contenders. The report also offers extensive research on the key players in this market and details on the competitiveness of these players. Key business strategies such as mergers and acquisitions (M&A), affiliations, collaborations, and contracts adopted by these major market participants are also recognized and analyzed in the report. For each company, the report studies their global presence, competitors, service offerings and specification amongst others.
The market for the syringe is highly fragmented, with a wide number of local and international players present. Key players pursue growing growth strategies to increase their Insulin Syringes Market presence, such as alliances, agreements, deals, new product releases, regional extensions, mergers, and acquisitions. The primary market participants include Novo Nordisk A/S, Sanofi S.A., Eli Lilly and Company, Biocon Ltd., Ypsomed AG, Wockhardt Ltd., Medtronic Plc, Abbott Laboratories, Animas Corporation, and F. Hoffmann-La Roche, Ltd.
Insulin Syringes Market:
- By End User
- Hospital
- Homecare
- Others
- By Sales Channel
- Online
- Offline
- By Geography
- North America
- US
- Canada
- Mexico
- Rest of North America
- Europe
- France
- The UK
- Spain
- Germany
- Italy
- Nordic Countries
- Denmark
- Finland
- Iceland
- Sweden
- Norway
- Benelux Union
- Belgium
- The Netherlands
- Luxembourg
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Southeast Asia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Rest of Southeast Asia
- Rest of Asia Pacific
- Middle East and Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Argentina
- Rest of Latin America
- North America
Table of Contents
1. Market
Scope
1.1. Market
Segmentation
1.2. Years
Considered
1.2.1. Historic
Years: 2013 - 2017
1.2.2. Base
Year: 2018
1.2.3. Forecast
Years: 2019 – 2027
2. Key Target
Audiences
3. Research
Methodology
3.1. Primary
Research
3.1.1. Research
Questionnaire
3.1.2. Global
Percentage Breakdown
3.1.3. Primary
Interviews: Key Opinion Leaders (KOLs)
3.2. Secondary
Research
3.2.1. Paid
Databases
3.2.2. Secondary
Sources
3.3. Market
Size Estimates
3.3.1. Top-Down
Approach
3.3.2. Bottom-Up
Approach
3.4. Data
Triangulation Methodology
3.5. Research
Assumptions
4. Recommendations
and Insights from AMI’s Perspective**
5. Holistic
Overview of Insulin Syringes Market
6. Market
Synopsis: Insulin Syringes Market
7. Insulin
Syringes Market Analysis: Qualitative Perspective
7.1. Introduction
7.1.1. Product
Definition
7.1.2. Industry
Development
7.2. Market
Dynamics
7.2.1. Drivers
7.2.2. Restraints
7.2.3. Opportunities
7.3. Trends in
Insulin Syringes Market
7.4. Market
Determinants Radar Chart
7.5. Macro-Economic
and Micro-Economic Indicators: Insulin Syringes Market
7.6. Porter’s
Five Force Analysis
8. Global
Insulin Syringes Market Analysis and Forecasts, 2019 – 2027
8.1. Overview
8.1.1. Global
Insulin Syringes Market Revenue (US$ Mn)
8.2. Global
Insulin Syringes Market Revenue (US$ Mn) and Forecasts, By End User
8.2.1. Hospital
8.2.1.1. Definition
8.2.1.2. Market
Estimation and Penetration, 2013 – 2018
8.2.1.3. Market
Forecast, 2019 – 2027
8.2.1.4. Compound
Annual Growth Rate (CAGR)
8.2.1.5. Regional
Bifurcation
8.2.1.5.1. North
America
8.2.1.5.1.1. Market
Estimation, 2013 – 2018
8.2.1.5.1.2. Market
Forecast, 2019 – 2027
8.2.1.5.2. Europe
8.2.1.5.2.1. Market
Estimation, 2013 – 2018
8.2.1.5.2.2. Market
Forecast, 2019 – 2027
8.2.1.5.3. Asia
Pacific
8.2.1.5.3.1. Market
Estimation, 2013 – 2018
8.2.1.5.3.2. Market
Forecast, 2019 – 2027
8.2.1.5.4. Middle
East and Africa
8.2.1.5.4.1. Market
Estimation, 2013 – 2018
8.2.1.5.4.2. Market
Forecast, 2019 – 2027
8.2.1.5.5. Latin
America
8.2.1.5.5.1. Market
Estimation, 2013 – 2018
8.2.1.5.5.2. Market
Forecast, 2019 – 2027
8.2.2. Home
care
8.2.2.1. Definition
8.2.2.2. Market
Estimation and Penetration, 2013 – 2018
8.2.2.3. Market
Forecast, 2019 – 2027
8.2.2.4. Compound
Annual Growth Rate (CAGR)
8.2.2.5. Regional
Bifurcation
8.2.2.5.1. North
America
8.2.2.5.1.1. Market
Estimation, 2013 – 2018
8.2.2.5.1.2. Market
Forecast, 2019 – 2027
8.2.2.5.2. Europe
8.2.2.5.2.1. Market
Estimation, 2013 – 2018
8.2.2.5.2.2. Market
Forecast, 2019 – 2027
8.2.2.5.3. Asia
Pacific
8.2.2.5.3.1. Market
Estimation, 2013 – 2018
8.2.2.5.3.2. Market
Forecast, 2019 – 2027
8.2.2.5.4. Middle
East and Africa
8.2.2.5.4.1. Market
Estimation, 2013 – 2018
8.2.2.5.4.2. Market
Forecast, 2019 – 2027
8.2.2.5.5. Latin
America
8.2.2.5.5.1. Market
Estimation, 2013 – 2018
8.2.2.5.5.2. Market
Forecast, 2019 – 2027
8.2.3. Others
8.2.3.1. Definition
8.2.3.2. Market
Estimation and Penetration, 2013 – 2018
8.2.3.3. Market
Forecast, 2019 – 2027
8.2.3.4. Compound
Annual Growth Rate (CAGR)
8.2.3.5. Regional
Bifurcation
8.2.3.5.1. North
America
8.2.3.5.1.1. Market
Estimation, 2013 – 2018
8.2.3.5.1.2. Market
Forecast, 2019 – 2027
8.2.3.5.2. Europe
8.2.3.5.2.1. Market
Estimation, 2013 – 2018
8.2.3.5.2.2. Market
Forecast, 2019 – 2027
8.2.3.5.3. Asia
Pacific
8.2.3.5.3.1. Market
Estimation, 2013 – 2018
8.2.3.5.3.2. Market
Forecast, 2019 – 2027
8.2.3.5.4. Middle
East and Africa
8.2.3.5.4.1. Market
Estimation, 2013 – 2018
8.2.3.5.4.2. Market
Forecast, 2019 – 2027
8.2.3.5.5. Latin
America
8.2.3.5.5.1. Market
Estimation, 2013 – 2018
8.2.3.5.5.2. Market
Forecast, 2019 – 2027
8.3. Key
Segment for Channeling Investments
8.3.1. By End
User
9. North
America Insulin Syringes Market Analysis and Forecasts, 2019 - 2027
9.1. Overview
9.1.1. North
America Insulin Syringes Market Revenue (US$ Mn)
9.2. North
America Insulin Syringes Market Revenue (US$ Mn) and Forecasts, By End User
9.2.1. Hospital
9.2.2. Home
care
9.2.3. Others
9.3. North
America Insulin Syringes Market Revenue (US$ Mn) and Forecasts, By Country
9.3.1. U.S
9.3.1.1. U.S
Insulin Syringes Market Revenue (US$ Mn) and Forecasts, By End User
9.3.1.1.1. Hospital
9.3.1.1.2. Home
care
9.3.1.1.3. Others
9.3.2. Canada
9.3.2.1. Canada
Insulin Syringes Market Revenue (US$ Mn) and Forecasts, By End User
9.3.2.1.1. Hospital
9.3.2.1.2. Home
care
9.3.2.1.3. Others
9.3.3. Mexico
9.3.3.1. Mexico
Insulin Syringes Market Revenue (US$ Mn) and Forecasts, By End User
9.3.3.1.1. Hospital
9.3.3.1.2. Home
care
9.3.3.1.3. Others
9.3.4. Rest of
North America
9.3.4.1. Rest
of North America Insulin Syringes Market Revenue (US$ Mn) and Forecasts, By End
User
9.3.4.1.1. Hospital
9.3.4.1.2. Home
care
9.3.4.1.3. Others
9.4. Key
Segment for Channeling Investments
9.4.1. By
Country
9.4.2. By End
User
10. Europe
Insulin Syringes Market Analysis and Forecasts, 2019 - 2027
10.1. Overview
10.1.1. Europe
Insulin Syringes Market Revenue (US$ Mn)
10.2. Europe
Insulin Syringes Market Revenue (US$ Mn) and Forecasts, By End User
10.2.1. Hospital
10.2.2. Home
care
10.2.3. Others
10.3. Europe
Insulin Syringes Market Revenue (US$ Mn) and Forecasts, By Country
10.3.1. France
10.3.1.1. France
Insulin Syringes Market Revenue (US$ Mn) and Forecasts, By End User
10.3.1.1.1. Hospital
10.3.1.1.2. Home
care
10.3.1.1.3. Others
10.3.2. The UK
10.3.2.1. The
UK Insulin Syringes Market Revenue (US$ Mn) and Forecasts, By End User
10.3.2.1.1. Hospital
10.3.2.1.2. Home
care
10.3.2.1.3. Others
10.3.3. Spain
10.3.3.1. Spain
Insulin Syringes Market Revenue (US$ Mn) and Forecasts, By End User
10.3.3.1.1. Hospital
10.3.3.1.2. Home
care
10.3.3.1.3. Others
10.3.4. Germany
10.3.4.1. Germany
Insulin Syringes Market Revenue (US$ Mn) and Forecasts, By End User
10.3.4.1.1. Hospital
10.3.4.1.2. Home
care
10.3.4.1.3. Others
10.3.5. Italy
10.3.5.1. Italy
Insulin Syringes Market Revenue (US$ Mn) and Forecasts, By End User
10.3.5.1.1. Hospital
10.3.5.1.2. Home
care
10.3.5.1.3. Others
10.3.6. Nordic
Countries
10.3.6.1. Nordic
Countries Insulin Syringes Market Revenue (US$ Mn) and Forecasts, By End User
10.3.6.1.1. Hospital
10.3.6.1.2. Home
care
10.3.6.1.3. Others
10.3.6.2. Nordic
Countries Insulin Syringes Market Revenue (US$ Mn) and Forecasts, By Country
10.3.6.2.1. Denmark
10.3.6.2.2. Finland
10.3.6.2.3. Iceland
10.3.6.2.4. Sweden
10.3.6.2.5. Norway
10.3.7. Benelux
Union
10.3.7.1. Benelux
Union Insulin Syringes Market Revenue (US$ Mn) and Forecasts, By End User
10.3.7.1.1. Hospital
10.3.7.1.2. Home
care
10.3.7.1.3. Others
10.3.7.2. Benelux
Union Insulin Syringes Market Revenue (US$ Mn) and Forecasts, By Country
10.3.7.2.1. Belgium
10.3.7.2.2. The
Netherlands
10.3.7.2.3. Luxembourg
10.3.8. Rest of
Europe
10.3.8.1. Rest
of Europe Insulin Syringes Market Revenue (US$ Mn) and Forecasts, By End User
10.3.8.1.1. Hospital
10.3.8.1.2. Home
care
10.3.8.1.3. Others
10.4. Key
Segment for Channeling Investments
10.4.1. By
Country
10.4.2. By End
User
11. Asia
Pacific Insulin Syringes Market Analysis and Forecasts, 2019 - 2027
11.1. Overview
11.1.1. Asia
Pacific Insulin Syringes Market Revenue (US$ Mn)
11.2. Asia
Pacific Insulin Syringes Market Revenue (US$ Mn) and Forecasts, By End User
11.2.1. Hospital
11.2.2. Home
care
11.2.3. Others
11.3. Asia
Pacific Insulin Syringes Market Revenue (US$ Mn) and Forecasts, By Country
11.3.1. China
11.3.1.1. China
Insulin Syringes Market Revenue (US$ Mn) and Forecasts, By End User
11.3.1.1.1. Hospital
11.3.1.1.2. Home
care
11.3.1.1.3. Others
11.3.2. Japan
11.3.2.1. Japan
Insulin Syringes Market Revenue (US$ Mn) and Forecasts, By End User
11.3.2.1.1. Hospital
11.3.2.1.2. Home
care
11.3.2.1.3. Others
11.3.3. India
11.3.3.1. India
Insulin Syringes Market Revenue (US$ Mn) and Forecasts, By End User
11.3.3.1.1. Hospital
11.3.3.1.2. Home
care
11.3.3.1.3. Others
11.3.4. New
Zealand
11.3.4.1. New
Zealand Insulin Syringes Market Revenue (US$ Mn) and Forecasts, By End User
11.3.4.1.1. Hospital
11.3.4.1.2. Home
care
11.3.4.1.3. Others
11.3.5. Australia
11.3.5.1. Australia
Insulin Syringes Market Revenue (US$ Mn) and Forecasts, By End User
11.3.5.1.1. Hospital
11.3.5.1.2. Home
care
11.3.5.1.3. Others
11.3.6. South
Korea
11.3.6.1. South
Korea Insulin Syringes Market Revenue (US$ Mn) and Forecasts, By End User
11.3.6.1.1. Hospital
11.3.6.1.2. Home
care
11.3.6.1.3. Others
11.3.7. Southeast
Asia
11.3.7.1. Southeast
Asia Insulin Syringes Market Revenue (US$ Mn) and Forecasts, By End User
11.3.7.1.1. Hospital
11.3.7.1.2. Home
care
11.3.7.1.3. Others
11.3.7.2. Southeast
Asia Insulin Syringes Market Revenue (US$ Mn) and Forecasts, By Country
11.3.7.2.1. Indonesia
11.3.7.2.2. Thailand
11.3.7.2.3. Malaysia
11.3.7.2.4. Singapore
11.3.7.2.5. Rest
of Southeast Asia
11.3.8. Rest of
Asia Pacific
11.3.8.1. Rest
of Asia Pacific Insulin Syringes Market Revenue (US$ Mn) and Forecasts, By End
User
11.3.8.1.1. Hospital
11.3.8.1.2. Home
care
11.3.8.1.3. Others
11.4. Key
Segment for Channeling Investments
11.4.1. By
Country
11.4.2. By End
User
12. Middle
East and Africa Insulin Syringes Market Analysis and Forecasts, 2019 - 2027
12.1. Overview
12.1.1. Middle
East and Africa Insulin Syringes Market Revenue (US$ Mn)
12.2. Middle
East and Africa Insulin Syringes Market Revenue (US$ Mn) and Forecasts, By End
User
12.2.1. Hospital
12.2.2. Home
care
12.2.3. Others
12.3. Middle
East and Africa Insulin Syringes Market Revenue (US$ Mn) and Forecasts, By
Country
12.3.1. Saudi
Arabia
12.3.1.1. Saudi
Arabia Insulin Syringes Market Revenue (US$ Mn) and Forecasts, By End User
12.3.1.1.1. Hospital
12.3.1.1.2. Home
care
12.3.1.1.3. Others
12.3.2. UAE
12.3.2.1. UAE
Insulin Syringes Market Revenue (US$ Mn) and Forecasts, By End User
12.3.2.1.1. Hospital
12.3.2.1.2. Home
care
12.3.2.1.3. Others
12.3.3. Egypt
12.3.3.1. Egypt
Insulin Syringes Market Revenue (US$ Mn) and Forecasts, By End User
12.3.3.1.1. Hospital
12.3.3.1.2. Home
care
12.3.3.1.3. Others
12.3.4. Kuwait
12.3.4.1. Kuwait
Insulin Syringes Market Revenue (US$ Mn) and Forecasts, By End User
12.3.4.1.1. Hospital
12.3.4.1.2. Home
care
12.3.4.1.3. Others
12.3.5. South
Africa
12.3.5.1. South
Africa Insulin Syringes Market Revenue (US$ Mn) and Forecasts, By End User
12.3.5.1.1. Hospital
12.3.5.1.2. Home
care
12.3.5.1.3. Others
12.3.6. Rest of
Middle East & Africa
12.3.6.1. Rest
of Middle East & Africa Insulin Syringes Market Revenue (US$ Mn) and
Forecasts, By End User
12.3.6.1.1. Hospital
12.3.6.1.2. Home
care
12.3.6.1.3. Others
12.4. Key
Segment for Channeling Investments
12.4.1. By
Country
12.4.2. By End
User
13. Latin
America Insulin Syringes Market Analysis and Forecasts, 2019 - 2027
13.1. Overview
13.1.1. Latin
America Insulin Syringes Market Revenue (US$ Mn)
13.2. Latin
America Insulin Syringes Market Revenue (US$ Mn) and Forecasts, By End User
13.2.1. Hospital
13.2.2. Home
care
13.2.3. Others
13.3. Latin
America Insulin Syringes Market Revenue (US$ Mn) and Forecasts, By Country
13.3.1. Brazil
13.3.1.1. Brazil
Insulin Syringes Market Revenue (US$ Mn) and Forecasts, By End User
13.3.1.1.1. Hospital
13.3.1.1.2. Home
care
13.3.1.1.3. Others
13.3.2. Argentina
13.3.2.1. Argentina
Insulin Syringes Market Revenue (US$ Mn) and Forecasts, By End User
13.3.2.1.1. Hospital
13.3.2.1.2. Home
care
13.3.2.1.3. Others
13.3.3. Rest of
Latin America
13.3.3.1. Rest
of Latin America Insulin Syringes Market Revenue (US$ Mn) and Forecasts, By End
User
13.3.3.1.1. Hospital
13.3.3.1.2. Home
care
13.3.3.1.3. Others
13.4. Key
Segment for Channeling Investments
13.4.1. By
Country
13.4.2. By End
User
14. Competitive
Benchmarking
14.1. Market
Share Analysis, 2018
14.2. Global Presence
and Growth Strategies
14.2.1. Mergers
and Acquisitions
14.2.2. Product
Launches
14.2.3. Investments
Trends
14.2.4. R&D
Initiatives
15. Player
Profiles
15.1. Abbott Laboratories
15.1.1. Company
Details
15.1.2. Company
Overview
15.1.3. Product
Offerings
15.1.4. Key
Developments
15.1.5. Financial
Analysis
15.1.6. SWOT
Analysis
15.1.7. Business
Strategies
15.2. Animas Corporation
15.2.1. Company
Details
15.2.2. Company
Overview
15.2.3. Product
Offerings
15.2.4. Key
Developments
15.2.5. Financial
Analysis
15.2.6. SWOT
Analysis
15.2.7. Business
Strategies
15.3. Biocon Ltd.
15.3.1. Company
Details
15.3.2. Company
Overview
15.3.3. Product
Offerings
15.3.4. Key
Developments
15.3.5. Financial
Analysis
15.3.6. SWOT
Analysis
15.3.7. Business
Strategies
15.4. Eli Lilly and Company
15.4.1. Company
Details
15.4.2. Company
Overview
15.4.3. Product
Offerings
15.4.4. Key
Developments
15.4.5. Financial
Analysis
15.4.6. SWOT
Analysis
15.4.7. Business Strategies
15.5.
F. Hoffmann-La Roche, Ltd.
15.5.1. Company
Details
15.5.2. Company
Overview
15.5.3. Product
Offerings
15.5.4. Key Developments
15.5.5. Financial
Analysis
15.5.6. SWOT
Analysis
15.5.7. Business
Strategies
15.6. Medtronic Plc
15.6.1. Company
Details
15.6.2. Company
Overview
15.6.3. Product
Offerings
15.6.4. Key
Developments
15.6.5. Financial
Analysis
15.6.6. SWOT
Analysis
15.6.7. Business
Strategies
15.7. Novo
Nordisk A/S
15.7.1. Company
Details
15.7.2. Company
Overview
15.7.3. Product
Offerings
15.7.4. Key
Developments
15.7.5. Financial
Analysis
15.7.6. SWOT
Analysis
15.7.7. Business
Strategies
15.8. Sanofi S.A.
15.8.1. Company
Details
15.8.2. Company
Overview
15.8.3. Product
Offerings
15.8.4. Key
Developments
15.8.5. Financial
Analysis
15.8.6. SWOT
Analysis
15.8.7. Business
Strategies
15.9. Wockhardt Ltd.
15.9.1. Company
Details
15.9.2. Company
Overview
15.9.3. Product
Offerings
15.9.4. Key
Developments
15.9.5. Financial
Analysis
15.9.6. SWOT
Analysis
15.9.7. Business
Strategies
15.10. Ypsomed AG
15.10.1. Company
Details
15.10.2. Company
Overview
15.10.3. Product
Offerings
15.10.4. Key
Developments
15.10.5. Financial
Analysis
15.10.6. SWOT
Analysis
15.10.7. Business
Strategies
15.11. Other
Market Participants
16. Key
Findings
Note: This ToC is tentative
and can be changed according to the research study conducted during the course
of report completion.
**Exclusive for Multi-User and
Enterprise User.
At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.
Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.
Prominent participants in our primary research process include:
- Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
- Research and development participants, distributors/suppliers and subject matter experts
Secondary Research includes data extracted from paid data sources:
- Reuters
- Factiva
- Bloomberg
- One Source
- Hoovers
Research Methodology
Key Inclusions
Reach to us
Call us on
+91-74002-42424
Drop us an email at
sales@absolutemarketsinsights.com
Why Absolute Markets Insights?
An effective strategy is the entity that influences a business to stand out of the crowd. An organization with a phenomenal strategy for success dependably has the edge over the rivals in the market. It offers the organizations a head start in planning their strategy. Absolute Market Insights is the new initiation in the industry that will furnish you with the lead your business needs. Absolute Market Insights is the best destination for your business intelligence and analytical solutions; essentially because our qualitative and quantitative sources of information are competent to give one-stop solutions. We inventively combine qualitative and quantitative research in accurate proportions to have the best report, which not only gives the most recent insights but also assists you to grow.